Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: Findings from a multi-ethnic US population

European Heart Journal

Volumn 30, Issue 6, 2009, Pages 710-717

  Sierra Johnson, Justo ^a,b   Fisher, Rachel M ^a   Romero Corral, Abel ^b   Somers, Virend K ^b   Lopez Jimenez, Francisco ^b   Öhrvik, John ^a   Walldius, Göran ^a,c   Hellenius, Mai Lis ^a   Hamsten, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Mayo Clinic   (United States)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

ApoB apoA I ratio; Apolipoprotein A I; Apolipoprotein B; Cardiovascular mortality; Cardiovascular risk factors; Coronary heart disease; HDL cholesterol; NHANES; Outcomes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; UNITED STATES;

AGE FACTORS; ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; BODY WEIGHTS AND MEASURES; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; UNITED STATES;

EID: 64949084931     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn347     Document Type: Article

References (34)

1. Olofsson SO, Wiklund O, Boren J. Apolipoproteins A-1 and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag 2007;3:491-502.
2. Walldius G, Jungner I. The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J intern Med 2006;259:493-519.
3. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein A1, the apolipoprotein B/A1 ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006;259:481-492.
4. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women JAMA 2007;298:776-785.
5. Sierra-Johnson J. Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Garni AS, Lopez-Jimenez F. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006;98:1369-1373.
6. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A, Hellenius ML, Fisher RM. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J 2007;28: 2637-2643.
7. Sniderman AD. The apoB/apoA-1 ratio and insulin resistance: sorting out the metabolic syndrome. Eur Heart ] 2007;28:2563-2564.
8. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F. Clinical utility of different lipid measures. JAMA 2008;299:35.
9. Sierra-Johnson J, Fisher RM. Is it time to discard the apolipoprotein B:apolipopro-tein A-I ratio as a predictor of cardiovascular disease? Nat Clin Pract Cardiovasc Med 2008;5:18-19.
10. National Center for Health Statistics. Office of Analysis and Epidemiology, Public-use NHANES III Linked Mortality file, 2007. Maryland, Hyattsville. http:// www.cdc.gov/nchs/r&d/nchs-datalinkage/nhanes3-data- linkage-mortality-activ-¡ties.htm (31 January 2008).
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497.
12. Grundy SM, Cleeman Jl, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F American Heart Association; National Heart, Lung, Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circuiation 2005;112:2735- 2752.
13. Chobanian A, Bakris G, Black H, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
14. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
15. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F. Association between body weight with mortality and with cardiovascular events in patients with coronary disease: a systematic review of cohort studies. Lancet 2006;368:666-678.
16. Romero-Corral A, Somers VK, Sierra-Johnson J, Jensen MD, Thomas RJ, Squires RW, Allison TG, Korinek J, Lopez-Jimenez F. Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. Eur Heart J 2007;28:2087-2093.
17. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952.
18. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358: 2026-2033.
19. Vaessen SF, Schaap FG, Kuivenhoven JA, Groen AK, Hutten BA, Boekholdt SM, Hattori H, Sandhu MS, Bingham SA, Luben R, Palmen JA, Wareham NJ, Humphries SE, Kastelein JJ, Talmud PJ, Khaw KT. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res 2006;47:2064-2070.
20. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apoIipo-protein AI ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). Am Heart J 2004;148:596- 601.
21. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005;26: 271-278.
22. Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardioi 2006;98:1047-1052.
23. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specif¡c excess deaths associated with underweight, overweight, and obesity. JAMA 2007;298: 2028-2037.
24. Saydah S, Graubard B, Ballard-Barbash R, Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol 2007;166:518.
25. Iribarren C, Crow RS, Hannon PJ, Jacobs DR Jr, Luepker RV. Validation of death certificate diagnosis of out-of-hospital sudden cardiac death. Am J Cardioi 1998;82: 50-53.
26. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365: 1415-1428.
27. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO Jr. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardioi 2007;18:1735-1741.
28. Sniderman AD, Holme I, Aastveit A, Furberg C, Walldius G, Jungner I. Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease. Am J Cardioi 2007;100:217-221.
29. Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 2005;26:210-212.
30. Walldius G, Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardioi 2007;22: 359-367.
31. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lob Med 2004;42:1355-1363.
32. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Core 2008;31:811-822.
33. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardioi 2008;51: 1512-1524.
34. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stot Rep 2001; 49:1 -32. http://www.cdc.gov/nchs/data/nvsr/nvsr49/ nvsr49-02.pdf (31 January 2008).